b976700360f03311af0ee916849fdcf4.jpg

About Us

Orion Genomics brings cutting edge scientific expertise, innovation, proprietary technologies and commercial and academic partnerships throughout the globe to change how the world approaches feeding, fueling and healing itself. With over 100 patents and patents pending, a research and clinical division, strong leadership, and advisory boards, Orion Genomics is uniquely positioned to provide strategic and technological support to partners in agriculture and human health.

The Genomics Research and Service Division has active biomarker discovery programs, the latest sequencing technologies and expertise in all areas of genomics research to support our strategic alliances and our internal product development pipeline.

The Clinical Research and Service Division is centered around our “CLIA-Certified” clinical laboratory. This laboratory allows us to seamlessly move assays from our research lab to a clinical lab where they can be further developed and tested in a regulated environment.

Orion Biosains is a fully-owned subsidiary of Orion Genomics, with headquarters in Kuala Lumpur, Malaysia. Orion Biosains is innovating agriculture through bioscience by supporting the oil palm industry in Southeast Asia with plans to expand globally. They are commercializing the joint discoveries of the Malaysian Palm Oil Board and Orion Genomics, offering technical expertise, flexible business solutions and strategic partnerships to oil palm seed producers and growers.

The Malaysian Palm Oil Board and Orion Genomics publish in Nature the discovery of the epigenetic cause of oil palm fruit mantling, leading the way for increased palm oil yield. (Ong-Abdullah et al. Nature http://dx.doi.org/10.1038/nature15365)

For Immediate Release
September 9, 2015

Contact:
Carolyn Hawley
Canale Communications for Orion Genomics
619-849-5375
This email address is being protected from spambots. You need JavaScript enabled to view it.

Discovery Made Possible with Orion Genomics’ MethylScope® Technology, Paves Way for a Simple DNA Test that Selects High Performers, Allowing for a More Sustainable Oil Palm Industry

Sept. 9, 2015 – St. Louis, MO and Kuala Lumpur, Malaysia – A multinational team from the Malaysian Palm Oil Board (MPOB), Orion Genomics, and Cold Spring Harbor Laboratory today announced the publication of a paper in Nature detailing the epigenetic cause of mantling – a catastrophic phenotype which results in low-yielding oil palm in a significant but unpredictable portion of plants that are propagated by cloning. The study showed that while palms with mantled fruit are genetically identical to their high performing parents, the loss of DNA methylation in a specific region of an oil palm genome containing a transposable element called ‘Karma’ is responsible for the low-yielding mantled fruit. The discovery was enabled by the combination of MPOB’s and the oil palm industry’s vast collection of highly characterized clonal palms with a solid knowledge of oil palm and tissue culture and Orion’s MethylScope® technology, a tool used to precisely map DNA methylation across entire genomes.

“Mantling has severely curtailed the ability of oil palm growers to take advantage of the significantly increased yield that cloned palms can have over palms produced from seed,” stated Datuk Dr. Choo Yuen May, Director General of MPOB. “Because oil palm producers have had no way of knowing at the time of planting which clonal palms will be productive and which will carry the low-yielding mantled phenotype, many were unable to take the risk that they may plant completely unproductive palms. With this discovery, it will now be possible to test palms at the nursery stage with a simple DNA test, and to select only high performing clonal palms for cultivation. Removing this risk is significant, because clonal palms have the potential to produce 20 to 30 percent more oil on the same planted area as palms grown from seedlings, and this will decrease pressure on natural rain forests.”

Although the crop is planted on 5 percent of global land dedicated to producing vegetable oil, the African and South American oil palms, Elaeis guineensis and E. oleifera, respectively, together account for 45 percent of the edible oil production worldwide. The crop is also the most efficient producer of oil, yielding ten times more edible oil per unit of land than soybean. However, oil palm grows in the tropics, and its expanded cultivation can threaten sensitive habitats. Advancements that enable increased yields on existing planted area can help increase the sustainability of oil palm cultivation.

Researchers from MPOB and the oil palm industry, Orion Genomics and Cold Spring Harbor Labs discovered that an epigenetic state they called Bad Karma resulted from the loss of DNA methylation of the oil palm Karma transposon embedded within an important flowering transcription factor gene. Low methylation of Karma disrupts the normal splicing of the gene, causing the low oil yielding mantled phenotype. However, when dense methylation of the transposon was present, an epigenetic state the research team called Good Karma, oil palm clones thrived in production fields. The discovery has led to the development of a simple, leaf-based test that can predict the mantling phenotype at a stage before clonal palms are planted in the field, years before the mantling phenotype would normally appear. The new approach will enable the exclusive cultivation of high-performing plants, further optimizing the use of environmentally sensitive land resources. The precision DNA test is being marketed by Orion Biosains, the Southeast Asian affiliate of Orion Genomics.

“We have had a long-standing collaboration with the MPOB that has successfully combined Orion’s strengths in genomics and precision agriculture with MPOB’s expertise in oil palm breeding, tissue culture and biology, and this combination has allowed us to discover together several important genetic characteristics of the oil palm that can help the industry increase yields without increasing planted area,” said Nathan Lakey, President and CEO of Orion Genomics, and co-founder and Chairman of Orion Biosains. “It is especially gratifying that Orion’s MethylScope technology, licensed from Cold Spring Harbor Laboratory, was instrumental in making this important discovery.”

Latest news